002294.SHE Shenzhen Salubris Pharmaceuticals Co Ltd
- Market cap
- CNY 33.3B
- P/E
- 46.7x
- P/B
- 3.85x
- ROE
- 11.9%
- Dividend yield
- 1.64%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is 002294.SHE undervalued?
Graham number002294.SHE trades 182.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Salubris Pharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Shenzhen Salubris Pharmaceuticals Co Ltd yet.
Shenzhen Salubris Pharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale…
Full company profileShenzhen Salubris Pharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Salubris Pharmaceuticals Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.48B | 3.83B | 4.15B | 4.65B | 4.47B | 2.74B | 3.06B | 3.48B | 3.37B | 4.01B | 5.05B |
| Gross Profit | 2.57B | 2.88B | 3.37B | 3.71B | 3.51B | 1.89B | 2.25B | 2.48B | 2.30B | 2.87B | 3.66B |
| Operating Income | 1.48B | 1.63B | 1.71B | 1.72B | 846M | 79.2M | 586M | 727M | 656M | 646M | 1.07B |
| EBITDA | 1.53B | 1.71B | 1.76B | 1.81B | 1.05B | 552M | 798M | 874M | 893M | 1.04B | 1.17B |
| Net Income | 1.27B | 1.40B | 1.45B | 1.46B | 715M | 60.9M | 534M | 637M | 580M | 602M | 1.03B |
| EPS | 1.21 | 1.33 | 1.39 | 1.39 | 0.69 | 0.06 | 0.50 | 0.58 | 0.52 | 0.54 | 0.92 |
| Balance Sheet | |||||||||||
| Total Assets | 5.39B | 6.53B | 6.86B | 7.90B | 7.73B | 6.93B | 9.24B | 9.76B | 9.40B | 10.5B | 11.2B |
| Total Liabilities | 691M | 1.07B | 706M | 1.03B | 1.07B | 1.34B | 1.20B | 1.78B | 1.34B | 1.71B | 2.44B |
| Shareholders' Equity | 4.59B | 5.36B | 6.05B | 6.66B | 6.49B | 5.51B | 8.03B | 7.94B | 8.02B | 8.71B | 8.67B |
| Cash & Short-term Investments | 1.03B | 1.78B | 1.68B | 1.25B | 1.32B | 1.08B | 3.30B | 3.00B | 1.51B | 1.86B | 1.10B |
| Total Debt | 60.0M | 60.0M | 30.0M | 242M | 283M | 398M | 72.1M | 197M | 52.5M | 124M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.06B | 1.43B | 1.46B | 1.34B | 1.51B | 1.37B | 1.18B | 971M | 839M | 1.19B | - |
| Capital Expenditure | 236M | 245M | 332M | 333M | 457M | 642M | 483M | 599M | 671M | 625M | 1.15B |
| Free Cash Flow | 820M | 1.19B | 1.13B | 1.01B | 1.05B | 732M | 702M | 372M | 168M | 561M | 190M |
| Ratios | |||||||||||
| ROE | 27.6% | 26.1% | 24.0% | 21.9% | 11.0% | 1.1% | 6.6% | 8.0% | 7.2% | 6.9% | 11.9% |
| ROA | 23.5% | 21.4% | 21.2% | 18.5% | 9.2% | 0.9% | 5.8% | 6.5% | 6.2% | 5.7% | 9.2% |
| Net Profit Margin | 36.4% | 36.4% | 35.0% | 31.3% | 16.0% | 2.2% | 17.5% | 18.3% | 17.2% | 15.0% | 20.3% |
| Debt to Equity | 0.01x | 0.01x | 0.00x | 0.04x | 0.04x | 0.07x | 0.01x | 0.02x | 0.01x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Salubris Pharmaceuticals Co Ltd dividends
- Dividend yield
- 1.64%
- Forward dividend
- 0.55 CNY
- Payout ratio
- 90.8%
- Ex-dividend date
- May 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | CNY 546M | 0.49 | 90.8% |
| 2023 | CNY 546M | 0.49 | 94.1% |
| 2022 | CNY 438M | 0.40 | 68.7% |
| 2021 | CNY 1.60M | 0.00 | 0.3% |
| 2020 | CNY 516M | 0.50 | 847.7% |
| 2019 | CNY 853M | 0.82 | 119.2% |
| 2018 | CNY 843M | 0.80 | 57.8% |
| 2017 | CNY 1.16B | 1.11 | 80.0% |
| 2016 | CNY 206M | 0.20 | 14.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 16:10 on Apr 24, 2015.
Who owns Shenzhen Salubris Pharmaceuticals Co Ltd
- Insiders 60.31%
- Institutions 8.42%
- Public & others 31.27%
- Shares outstanding 1.11B
- Free float 444M
Shenzhen Salubris Pharmaceuticals Co Ltd company profile
- Company name
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Ticker
- 002294.SHE
- ISIN
- CNE100000FW8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Sep 10, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,087
- Fiscal year end
- December
- Address
- No. 289 Digital Peninsula, Shenzhen, China, 518017
- Phone
- 86 755 8386 7888
- Website
- salubris.com
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, electrophysiology, and cardiac rhythm management. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris Pharmaceuticals Co Ltd management
6- Mr. Jie YanGM & Director · born 1972
- Ms. Yun Kong CPACFO, Accounting Supervisor & Financial Manager · born 1973
- Mr. Ping ChenDeputy General Manager · born 1970
- Mr. Jianfeng YangSecretary of the Board of Directors & Non Independent Director · born 1975
- Ms. Song Ping ZhaoDeputy General Manager · born 1970
- Dr. Xie Heng M.D., Ph.D.Chief Medical Officer